Crispr/Cas9 : from patent disputes to the widespread use of GMOs
A dispute over patent rights to Crispr/Cas9 has been ongoing for several years between its main discoverers, universities and research institutes. To date, the outcome of this dispute and its impact on the Crispr/Cas9 economy remain unpredictable. Added to this is an ongoing dispute over Crispr applications between the parties to the main dispute and companies. Despite this, the widespread use of this tool for modifying living organisms, and the associated health, environmental and socio-economic consequences, seem inevitable.
Few micro-organisms modified by Crispr are already on the market
